KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Common Equity (2017 - 2025)

Historic Common Equity for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to -$110.0 million.

  • Amneal Pharmaceuticals' Common Equity fell 1751.47% to -$110.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$110.0 million, marking a year-over-year decrease of 1751.47%. This contributed to the annual value of -$109.5 million for FY2024, which is 64725.9% down from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Common Equity of -$110.0 million as of Q3 2025, which was down 1751.47% from -$112.5 million recorded in Q2 2025.
  • Over the past 5 years, Amneal Pharmaceuticals' Common Equity peaked at $407.4 million during Q1 2022, and registered a low of -$132.0 million during Q1 2025.
  • Over the past 5 years, Amneal Pharmaceuticals' median Common Equity value was $150.8 million (recorded in 2023), while the average stood at $118.3 million.
  • In the last 5 years, Amneal Pharmaceuticals' Common Equity soared by 1109.85% in 2022 and then tumbled by 64725.9% in 2024.
  • Amneal Pharmaceuticals' Common Equity (Quarter) stood at $367.0 million in 2021, then crashed by 49.87% to $184.0 million in 2022, then tumbled by 89.12% to $20.0 million in 2023, then tumbled by 647.26% to -$109.5 million in 2024, then fell by 0.4% to -$110.0 million in 2025.
  • Its Common Equity stands at -$110.0 million for Q3 2025, versus -$112.5 million for Q2 2025 and -$132.0 million for Q1 2025.